Taubert Jennifer L 4

What Happened Jennifer L. Taubert, EVP, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, received 27,412 performance share units (PSUs) reported on a Form 4 with transaction date 2026-02-09. The award is recorded at $0.00 (no cash paid) and is a derivative grant that will convert into common stock upon satisfying vesting and performance conditions. This is a compensation grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-09; Form 4 filed: 2026-02-11
• Award type/price: Performance Share Units (derivative award) at $0.00; amount: 27,412 PSUs
• Shares owned following transaction: not specified in the filing
• Footnotes: F1 — PSUs were originally granted under the issuer’s Long-Term Incentive Plan on Feb 13, 2023 and convert to common stock upon vesting. F2 — The 27,412 figure reflects the target grant adjusted for performance and was certified on Feb 9, 2026.
• Timeliness: Filing appears timely (Form 4 submitted within the expected 2-business-day window).

Context PSUs are performance-based compensation that only become actual shares if performance metrics and vesting conditions are met, so this grant does not represent an immediate market buy or sell. For retail investors, awards are routine executive compensation; direct purchases or sales by insiders are typically more informative about insider sentiment.